ObjectiveHealth Launches Feasibility and Recruitment Platform, ObjectiveScreen
AI-powered platform will allow clinical trial sites to connect directly with patient EHRs.
ObjectiveHealth has announced the launch of ObjectiveScreen, an AI feasibility and recruitment platform that seeks to provide patient identification, prequalification, and retention.
Powered by ObjectiveHealth’s cloud-based, AI and ML algorithms, ObjectiveScreen allows clinical trial sites to connect directly with patient electronic health records (EHRs). Patient health risks are stratified against evidence-based physiologic and molecular biomarkers so users can identify in the most qualified candidates for specific clinical trials.
Each time an EHR is linked, ObjectiveScreen’s algorithms analyze the health data, updating its clinical knowledge base while qualifying patients for the specific trials.
In addition to EHR analysis, ObjectiveScreen can review other patient data, including risk factors and demographic data such as age, gender, ethnicity and socioeconomic status, which can help identify candidates who may not have a diagnosis.
By linking with a healthcare provider’s scheduling application, users of ObjectiveScreen can arrange prescreen visits. ObjectiveScreen’s texting and calling capabilities allow clinical trial site users to communicate directly with patients about appointment reminders and rescheduling options. Users can also monitor patients over multiple visits and recommend new studies if patients did not qualify for a previous trial.
Reference
ObjectiveHealth Launches ObjectiveScreen, an Artificial Intelligence-Powered Feasibility and Recruitment Platform to Optimize Clinical Trial Performance. (2023, June 8). Business Wire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025